ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1737

Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital

Catalina Gómez-Arango1, M. Luz García-Vivar1, Montserrat Alonso-Diez2, M. Milagros Alvarez-Lavin2, Eva Galindez-Agirregoikoa3, Olaia Fernández-Berrizbeitia3, Esther Ruíz-Lucea1, Juan María Blanco-Madrigal1, Jose Francisco Garcia-Llorente1, Lidia Estopiñán-Fortea3, Ignacio Torre-Salaberri4, Edurne Guerrero-Basterretxea3, Itziar Calvo-Zorrilla3, Amaia Bilbao-González5 and Natalia Rivera-García5, 1Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, 2Pharmacy Department, Basurto University Hospital, Bilbao, Spain, 3Rheumatology Department, Basurto University Hospital, Bilbao, Spain, 4Rheumaytology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, 5Research Department, Basurto University Hospital, Bilbao, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: arthritis management, Compliance, Rheumatoid arthritis (RA), spondylarthritis and therapy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Rheumatic inflammatory arthropaties such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthrities (SpA) are chronic diseases that require adequate therapies, sometimes biological drugs, to minimize inflammation and disease progression. The adherence to biologicals is supposed to be better than adherence to synthetic DMARDs, mainly methotrexate. The purpose of this study is to evaluate adherence to subcutaneous biological therapies and to assess the relationship between adherence and different demographic and clinical aspects, and its effect on clinical outcomes.

Methods:  Observational retrospective study of 272 clinical records of patients with inflammatory rheumatic diseases on subcutaneous biological treatment, were reviewed. Demographic, clinical characteristics and comorbidities were compiled. Disease activity was classified as low, moderate and high based on DAS 28 in patients with peripheral arthritis and BASDAI in patients with axial SpA. Adherence was obtained for the last year from the Hospital Pharmacy registry (FARHOS). Adherence was randomly rated as good >80% of compliance, medium 60-79% and fair <59%. 11 patients not actually under biological treatment were excluded from analysis. Statistical analyses were performed using SAS for Windows statistical software, version 9.2.

Results:  From the 261 patients evaluated, 52% were female, mean aged 54 + 13.9 SD years (range 19-86). 35.6 % had RA diagnosis, 32% PsA, 29.5% axial SpA and, 6% peripheral SpA and 1% non-radiographic axial SpA. Median time of disease progression was 10.7 years. 34% presented more than two comorbidities.39% were under adalimumab, 38 % etanercept, 7.3% golimumab, 5.4% certolizumab, 4.6% tocilizumab, 2,7 % abatacept and 1% ustekinumab. 68 % were on their first biological drug, 25% on the second, and the rest had more than one biologic agent previously prescribed. 46 received concomitant synthetic DMARD. Overall adherence to biological treatment, was good, 93%, and there was no correlation between adherence and diagnose, gender, age, time of disease progression, concurrence of more than two comorbidities, cotreatment with synthetic DMARD, type of biological drug or previous treatment with other biologicals. There has been found correlation between disease activity (DAS, BASDAI) and adherence as shown in the table, P 0.0038 (Chi Square).

Conclusion: The overall adherence to subcutaneous biological therapies is very good and non-compliance has an impact in the disease activity as has been observed in this study. Therefore, it is important to check adherence when clinical response is poor to subcutaneous biological therapies and we must consider the implementation of tools to monitor adherence in order to identify non-compliant patients, quite relevant for clinical decision making.


Disclosure: C. Gómez-Arango, None; M. L. García-Vivar, None; M. Alonso-Diez, None; M. M. Alvarez-Lavin, None; E. Galindez-Agirregoikoa, None; O. Fernández-Berrizbeitia, None; E. Ruíz-Lucea, None; J. María Blanco-Madrigal, None; J. F. Garcia-Llorente, None; L. Estopiñán-Fortea, None; I. Torre-Salaberri, None; E. Guerrero-Basterretxea, None; I. Calvo-Zorrilla, None; A. Bilbao-González, None; N. Rivera-García, None.

To cite this abstract in AMA style:

Gómez-Arango C, García-Vivar ML, Alonso-Diez M, Alvarez-Lavin MM, Galindez-Agirregoikoa E, Fernández-Berrizbeitia O, Ruíz-Lucea E, María Blanco-Madrigal J, Garcia-Llorente JF, Estopiñán-Fortea L, Torre-Salaberri I, Guerrero-Basterretxea E, Calvo-Zorrilla I, Bilbao-González A, Rivera-García N. Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/adherence-to-subcutaneous-biological-therapies-among-inflammatory-arthropaty-patients-from-a-university-hospital/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-subcutaneous-biological-therapies-among-inflammatory-arthropaty-patients-from-a-university-hospital/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology